



European Monitoring Centre
for Drugs and Drug Addiction

Update from the EMCDDA

Public Health Unit - EMCDDA

CSF meeting, Luxembourg, 17 June 2019



Overview

Two new reports: highlights

Elimination agenda: progress

Support to countries to increase access to HCV treatment and care for PWID (EMCDDA Harm Reduction Initiative)

Outlook 2019/2020



New reports (June 2019)

Trends in drug use and drug-related infections



European Monitoring Centre
for Drugs and Drug Addiction

EN

European Drug Report

Trends and Developments

2019



European Monitoring Centre
for Drugs and Drug Addiction

RAPID COMMUNICATION

Drug-related infectious diseases in Europe

Update from the EMCDDA expert network
June 2019



EDR 2019: The package

Trends and Developments

providing a top-level analysis of key developments (print and PDF)



Country Drug Reports

graphic-rich reports presenting summaries of national drug phenomena (online)

EU 28, Turkey and Norway

Statistical Bulletin
containing full data arrays and methodological information (online)



EDR 2019: Highlights

Get the facts



Cocaine: record seizures, new distribution methods and evidence of growing health problems

Synthetic opioids: acute poisonings and deaths a concern, opioid-containing medicines appear to play increasing role in drug problems

Heroin: increased quantity of heroin+precursors seized; more laboratories detected

NPS: diversity of substances; problematic use patterns observed in marginalised groups


Cannabis: increased potency, new production techniques; main drug reported for new treatment entrants

European
Drug
Report


Trends and Developments

2019

HIV among PWID




Gender




(N = 1067)

Age (years)



(N = 1007)

CD4 counts (cells/cm³)




(N = 628)

- **Decline** in new HIV notifications ongoing: < 2/million;
- **Local HIV outbreaks** linked to injecting of stimulants: Munich, Glasgow, Luxembourg;
- **Prison HIV outbreak** in Lithuania; effective prevention limited/unavailable;
- **HIV/AIDS burden** high in countries with old epidemics;

Data: ECDC and WHO, 2018.

HCV-ab prevalence in PWID



Source: EMCDDA Rapid Communication DRID, 2019



Eliminating viral hepatitis as public health threat


Elimination barometer for PWID in Europe

Area	Indicator	Related 2020 target
CONTEXT AND NEED	<ul style="list-style-type: none"> Number of PWID Main drugs injected Sharing of needles/syringes Prevalence of HCV and HBV 	<ul style="list-style-type: none"> ✓ Indicators available and context documented
INPUTS	<ul style="list-style-type: none"> Hepatitis national policy/action plan inclusive of PWID 	<ul style="list-style-type: none"> ✓ National policy adopted
PREVENTION	<ul style="list-style-type: none"> Needles/syringes coverage Opioid substitution treatment coverage HBV vaccination availability in prison 	<ul style="list-style-type: none"> ✓ 200 per PWID per year ✓ 40% in treatment ✓ Targeted vaccination in place
TESTING & LINKAGE TO CARE	<ul style="list-style-type: none"> HCV/HBV testing availability in drug facilities/prisons Proportion of PWID tested for HCV in the last year Notifications of acute and chronic HVC/HBV cases DAA treatment availability for PWID 	<ul style="list-style-type: none"> ✓ 50% of PWID with chronic HCV/HBV diagnosed ✓ 75% of eligible patients treated
IMPACT	<ul style="list-style-type: none"> Prevalence of HCV among young and new PWID (proxy for incidence) 	<ul style="list-style-type: none"> ✓ 30% reduction (baseline =2015)

EMCDDA list of indicators and related 2020 WHO-targets.



OST coverage: EU average above 2020 WHO target but some countries far below; missing POU estimates




Estimated number of problem opioid users divided by number of reported cases in OST.
 Source: EMCDDA Rapid Communication DRID, 2019



Syringe coverage: most countries below WHO target

Only four countries above; missing PWID estimates




Number of syringes given out by official NSPs, per estimated person who injects drugs in 2017. Source: EMCDDA Rapid Communication DRID, 2019



HCV testing among PWID entering treatment

Source: TDI network. Self-report, 2017




Source: EMCDDA Rapid Communication DRID, 2019



Increasing access to HCV testing and care in drugs services

EMCDDA Harm reduction initiative: Increasing access to HCV testing in drugs services





EMCDDA Harm Reduction Initiative

Increasing access to HCV Testing and Treatment in Drugs Services

A manual for undertaking a diagnostic process to identify barriers and opportunities for increasing HCV testing in drugs services for PWID in Europe

(Contract code: CT.18.HEA.00091.1.0)



EMCDDA Viral Hepatitis Resource Area

Diagnostic Tool ----- Models of care ----- 'Library of materials'
Manual and Checklist database *Knowledge Questionnaire*



Hep C Initiative Module 1: diagnostic process

What: Diagnostic process to identify barriers and opportunities to HCV testing and care for PWID at system-, provider- and client level

Who: Multi-disciplinary: policy makers, service providers, service users. Close collaboration between national Focal Points Infectious Diseases and Drugs

How: Needs-assessment (barometer) + roundtable + action plan

Where: Country or regional/city level

Piloted in Luxembourg (Jan) and Poland (June), Launch October 2019

Consultants: I. Sperle-Heupel
& R Zimmermann, RKI Berlin

EMCDDA Harm Reduction Initiative

Increasing access to HCV Testing and
Treatment in Drugs Services

*A manual for undertaking a diagnostic process to identify
barriers and opportunities for increasing HCV testing in
drugs services for PWID in Europe*



(Contract code: CT.18.HEA.00091.1.0)



Modules 2: Response selection and 3: implementation

Eleven case studies New Models of care

Traditional **models of care** determined by interferon-based treatment regimens and based on referral of client to hospital (tertiary care).
High loss to follow-up among PWID



Need to **bring HCV care to the community** where PWID access services

Compilation of 11 case studies from Europe illustrating **new models of HCV testing and treatment** that complement and replace traditional referral models

Reference: **Effective strategies to enhance testing, linkage to and retention in care and treatment for PWID.** Treloar, C. & Grebely, J. 2019



Module 3: Library of materials to support staff

The Knowledge Questionnaire

EMCDDA Harm Reduction Initiative - Increasing HCV testing and referral in drug services for PWID

Knowledge questionnaire for drug service staff

How much do you know about viral hepatitis and the tests and treatment available? This short questionnaire will help us find out which topics people tend to be less sure about so that more information and training in these areas can be provided – and we hope it will be a useful knowledge refresher for you!

0% 100%

English

A. Hepatitis C

*** The level of hepatitis C in the general population in Europe is generally low (below 2%)**

I knew this already
 This is new to me

*** The level of hepatitis C among people who inject drugs in Europe is generally high (often 50%) or even higher)**

I knew this already
 This is new to me

*** Hepatitis C testing and treatment has benefits for both the individuals treated and for others, as the transmission of the virus is reduced**

I knew this already
 This is new to me

*** Hepatitis C is transmitted through blood.**

I knew this already
 This is new to me

40 simple statements on viral hepatitis:

- "I knew this already"
- "This is new to me"

A simple tool to assess training needs, or start a conversation...


7 languages: EN, DE, FR, IT, PL, EE, RUS

Tested by more than 100 respondents working in the field.

Consultants: I. Sperle-Heupel & R Zimmermann, RKI Berlin



Next Milestones



**LISBON
ADDICTIONS
2019**

28 July 2019

- Hepatitis C elimination barometer (techn.paper)
- Compendium: Case studies new Models of care
- Knowledge Questionnaire

LXAddictions “Futures” 23-25 October 2019

- Big debate: Involvement Civil Society & affected communities in addiction policies and practice
- Full set of materials and tools HCV Initiative
- Update HepC policy landscape in Europe

Viral hepatitis policies in Europe

Outlook for 2020

- Training module for interested national Focal Points
- Adaptation of new materials HCV initiative in EU4MD, IPA7 projects
- Health and Social Responses: a European Guide 2nd edition: **YOUR INPUT**



Visit us at emcdda.europa.eu

Watch the EDR 2019 video

<https://www.youtube.com/watch?v=GpJn2Mmt1Ok&feature=youtu.be>

Download the EDR in 24 languages

Download as PDF



Bulgarian (bg) Croatian (hr) Czech (cs) Danish (da) Dutch (nl) English (en) Estonian (et)
Finnish (fi) French (fr) German (de) Greek (el) Hungarian (hu) Italian (it) Latvian (lv)
Lithuanian (lt) Norwegian (no) Polish (pl) Portuguese (pt) Romanian (ro) Slovakian (sk)
Slovene (sl) Spanish (es) Swedish (sv) Turkish (tr)

Thank you for your attention

